PROGRAMME

Check this page regularly for updates

Monday 30 May
Education Session

08:00-09:00

Registration

09:00-10:30

Parallel 1a: Gene delivery platform

Chairs: Virginia Haurigot, Spark Therapeutics


09:00    Virginia Haurigot, Spark Therapeutics

INV01    AAV vectors, from basics to challenges


09:25    Xavier Anguela, Ask Bio

INV02   Non-viral gene transfer for rare diseases

ABSTRACT >


09:50    Pedro Berraondo, Program of Immunology and Immunotherapy, Cima Universidad de Navarra  

INV03    Advances in mRNA-based therapeutics


10:15    Round Table

09:00-10:30

Parallel 1b: Cellular Therapy

Chairs: Javier Garcia Castro, Instituto de Salud Carlos III, Madrid 


09:00    Pablo Menendez, Josep Carreras Leukaemia Research Institute, Barcelona  

INV04    CAR-based adoptive T-cell immunotherapies

ABSTRACT >


09:25    Aida Platero-Luengo, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC  

INV05    Crossing new frontiers in regenerative medicine: the reprogramming technology in cell therapy and aging

ABSTRACT >


09:50    Javier Garcia Castro, Instituto de Salud Carlos III, Madrid  

INV06    The state of the art in Cellular Therapy


10:15    Round Table

10:30-11:00

Break

 

Monday 30 May

12:30-13:30

Lunch and Biennial Congress Registration

12:30-13:30

Plenary 1: Inaugural session

Chair: Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona; JuanJo Toledo-Aral, Universidad de Sevilla


13:30    Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona  

SETGYC since 2019: Society update


13:45    Mariano Esteban, CNB-CSIC, Cantoblanco, Madrid

INV13    Lessons and challenges in the development of the vaccine MVA-CoV2-S/COVID-19

ABSTRACT >

14:45-16:15

Parallel 3a: Gene delivery platforms

Chair: Karim Benabdellah, GENYO, Granada


14:45    Els Verhoeyen, ENS Lyon, Université de Nice  

INV15    Novel lentiviral pseudotypes for T and NK cell gene therapy and ‘nanoblades’ for efficient gene editing in hematopoietic gene therapy target cells and organoids 

ABSTRACT >


15:15    Pedro Berraondo, Program of Immunology and Immunotherapy, Cima Universidad de Navarra

INV16    Messenger RNA in cancer immunotherapy


15:45  Pilar Martin Duque, Universidad de Zaragoza

OR01    Use and isolation of maternal milk exosomes: New vector for genetic hNIS therapy and diagnostic in oncology

ABSTRACT >


16:00  Carlos Blanco-Benitez, LentiStem Biotech. GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government.PTS Granada

OR02    Lent-On-Plus: An all-in-one transactivator-free doxycycline inducible LVs ready for clinical applications

ABSTRACT >


14:45-16:15

Parallel 3b: Pluripotent stem cells & organoids

Chair: Ricardo Pardal, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/


14:45    Nuria Montserrat, Institute for Bioengineering of Catalonia (IBEC)

INV17    Human pluripotent stem cells derived organoids: challenges and opportunities to study human development and disease


15:15    Isabel Fariñas, Departamento de Biología Celular, Biología Funcional y Antropología Física, Universidad de Valencia  

INV18    The impact of neural stem cell heterogeneity on niche dynamics


15:45    Beatriz Fernandez-Muñoz, Red Andaluza de Diseño y Traslación de Terapias Avanzadas, Sevilla
OR03     Using organoids to evaluate safety and potency of cell therapies

ABSTRACT >


16:00    Ainhoa Irastorza-Lorenzo, Biodonostia Institute, San Sebastian
OR04     Development of biomimetic tympanic membrane substitutes for the treatment of chronic perforations

ABSTRACT >

16:15-17:15

Break and Poster Session 1

 

Tuesday 31 May

08:00-09:00

Registration

09:00-09:30

Plenary 3: Safety

Chair:  Juan Bueren, CIEMAT, Madrid


09:00    Zoltan Ivics, Paul Ehrlich Institute, Langen  

INV26    Non-viral engineering of therapeutic cells with the Sleeping Beauty transposon system

ABSTRACT >

09:30-10:00

Advances therapies move to patients

Chair:  Gloria Gonzalez-Aseguinolaza, University of Navarra, Pamplona


09:30    Juan Bueren, CIEMAT, Madrid  Cristian Smerdou, CIMA Universidad de Navarra, Pamplona

INV27   Towards the implementation of gene therapy in the clinical practice

ABSTRACT >

10:00-11:30

Parallel 5a: CAR-T cells

Chair: José Antonio Pérez-Simón, Institute of Biomedicine of Sevilla


10:00    Antonio Perez-Martinez, Hospital Universitario La Paz, Madrid  

INV28    Cell therapy based on the Chimeric receptor NKG2D

ABSTRACT >


10:30    Valentin Ortiz, Hospital Clínic de Barcelona

INV29   CART19-BE-01: A European academic trial on the administration of ARI-0001 cells in patients with acute lympoblastic leukemia and other CD19+ lympoproliferative disorders


11:00    Angel Martin Mallo, Cima Universidad de Navarra. IdiSNA.

OR09    Effect of the disease stage over the phenotype and functionality of CAR-T cells in multiple myeloma patients

ABSTRACT >


11:15   Diego Sanchez-Martínez, Josep Carreras Leukemia Research Institute

OR10   Efficient treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-AntigenA T cell engagers

ABSTRACT >

10:00-11:30

Parallel 5b: Cell and gene therapy of Neural diseases

Chair: Juan José Toledo-Aral, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla


10:00    Benedikt Berninger, Institute of Psychiatry, Psychology & Neuroscience Centre for Developmental Neurobiology & MRC Centre for Neurodevelopmental Disorders, King's College London  

INV30    Advancing in vivo glia-to-neuron reprogramming as an innovative approach for brain repair: promises, disappointments, and breakthroughs

ABSTRACT >


10:30    Juan Ruiz, Forge Therapeutics 

INV31    The RESKUE Trial - a Phase 1/2 Clinical Trial for Patients with Krabbe Disease


11:00   Sergi Verdés, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB)

OR11    Gene therapy for ALS by specifically overexpressing a pleiotropic chronokine, secreted α-Klotho (s-KL), in skeletal muscles

ABSTRACT >


11:15    Nieves Iria Domínguez-García, Instituto de Biomedicina de Sevilla (IBiS)

OR12    Pathophysiological alterations of regulatory T cells in Parkinson's disease and generation of aSyn-CAR-Tregs as a novel therapeutic approach

ABSTRACT >

 

Wednesday 1 June
Ex Vivo and In Vivo Gene Editing: Present and Future Clinical Applications

08:30-09:00

Registration

09:00-10:30

Plenary 6: New gene editing tools

Chairs: Raul Torres, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid; Marc Güell, Universitat Pompeu Fabra, Barcelona


09:00    Julian Grünewald, Technical University of Munich

INV48    Engineered CRISPR prime editors with compact, untethered reverse transcriptases

ABSTRACT >


09:30    Pilar Puig-Serra, CNIO, Madrid  

INV49    Targeting and detection of cancer fusion oncogenes using CRISPR/Cas13

ABSTRACT >


10:00   Guillermo Güenechea Amurrio, CIEMAT, CIBERER, Madrid

OR20   Editing of Telomerase RNA Component gene in hematopoietic stem cells: An alternative tool to treat bone marrow failure in patients with autosomal dominant dyskeratosis congenita

ABSTRACT >


10:15   Isabel Ojeda-Perez, CIEMAT, CIBERER, Mardid

OR21   Studying Hematopoietic Stem Cell clonality in Gene Editing Strategies using DNA Barcoding

ABSTRACT >

10:30-12:00

Plenary 7: Gene editing ex vivo

Chairs: Francisco Martin, Genyo, Granada; Paula Rio, CIEMAT, Madrid


10:30    Annarita Miccio, Imagine Institute, Paris

INV50    Genome editing approaches for beta-hemoglobinopathies

ABSTRACT >


11:00    Alessia Cavazza, UCL, London

INV51    Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome


11:30    Matthew Porteus, Stanford University

INV52    Genome Editing of Hematopoietic Stem Cells

12:00-12:30

Break

12:30-13:30

Plenary 8: in vivo Gene editing applications

Chairs: Gloria Aseguinolaza, University of Navarra, Pamplona; Juan Bueren, CIEMAT, Madrid


12:30    Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona  

INV53  In vivo gene editing to treat Primary hyperoxaluria type I

ABSTRACT >


13:00    Jordi Barquinero, Vall d'Hebron Research Institute, Barcelona  

INV54    In vivo gene editing for Mitochondrial NeuroGastroIntestinal Encephalomyopathy 

ABSTRACT >


13:30    Ignacio Perez de Castro, Instituto de Salud Carlos III, Madrid

OR22    CRISPR-based strategies revert the LMNAᴿ²⁴⁹ᵂ induced phenotype both in cultured cells and in vivo

ABSTRACT >